通过靶向肿瘤相关巨噬细胞的嵌合受体工程化溶瘤病毒重振内源性抗肿瘤免疫
Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
放疗作为胰腺癌免疫治疗的伙伴：当前格局与未来方向
英文原题：Radiotherapy as a partner for immunotherapy in pancreatic cancer: current landscape and future directions.
查看英文原题
Radiotherapy as a partner for immunotherapy in pancreatic cancer: current landscape and future directions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胰腺导管腺癌（PDAC）的发病率持续上升，由于其起病隐匿且总生存期极差，它仍然是最致命的实体瘤之一。目前的治疗选择——手术、化疗和放疗——对大多数患者获益有限，这很大程度上是因为肿瘤致密的间质结构、深度免疫抑制的微环境以及对常规治疗的固有耐药性。近年来，免疫检查点抑制剂（ICIs）、癌症疫苗、溶瘤病毒和过继细胞疗法方面的进展推动了PDAC免疫治疗领域的稳步发展。与此同时，将免疫治疗与放疗、靶向药物或化疗相结合的多模式策略已开始显示出有前景的协同活性。本综述总结了PDAC单药及联合免疫治疗方法的最新进展，并强调了改善治疗结局的关键挑战和未来方向。
展开英文摘要原文
Pancreatic ductal adenocarcinoma (PDAC) continues to rise in incidence and remains one of the deadliest solid tumors due to its insidious onset and extremely poor overall survival. Current therapeutic options-surgery, chemotherapy, and radiotherapy-offer limited benefit for most patients, largely because of the tumor's dense stromal architecture, profoundly immunosuppressive microenvironment, and inherent resistance to conventional treatments.
In recent years, advances in immune checkpoint inhibitors (ICIs), cancer vaccines, oncolytic viruses, and adoptive cell therapies have driven steady progress in the field of PDAC immunotherapy. At the same time, multimodal strategies that combine immunotherapy with radiotherapy, targeted agents, or chemotherapy have begun to show promising synergistic activity.
This review summarizes the recent developments in both single-agent and combination immunotherapeutic approaches for PDAC, and highlights the key challenges and future directions for improving treatment outcomes.
论文信息
- 作者
- Diao Z、Wang Y、Mu S、Wu X、Yu S、Wang Z
- 第一作者单位
- School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.China
- 通讯作者单位
- Department of Radiation Oncology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in oncology2026
- 原文标识
- PubMed 41939454 · DOI 10.3389/fonc.2026.1756245